With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.
Helen Chu, MD, MPH
Advertisement
Chu is professor of Medicine, Epidemiology, and Global Health at the University of Washington.
Articles by Helen Chu, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial
2
Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections
3
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
4
New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine
5
